BI 1015550

Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3
Pharmaphorum
Thu, 10/27/22 - 10:41 am
Boehringer Ingelheim
BI 1015550
IPH
Boehringer secures FDA’s Breakthrough Therapy Designation for oral therapy
Pharmaceutical Business Review
Fri, 02/25/22 - 09:58 am
Boehringer Ingelheim
idiopathic pulmonary fibrosis
FDA
BI 1015550
breakthrough status